BIOMARKER:

KRAS exon 2 mutation

C2 | Sensitive

C3 | Sensitive

C2 | Resistant

C3 | Resistant

Show legend

Drug categories

Tyrosine Kinase Inhibitors

EGFR

Threonine-Tyrosine Kinase Inhibitors

Colorectal Cancer

Non Small Cell Lung Cancer

Pancreatic Cancer

selumetinib

KRAS exon 2 mutation|Colorectal Cancer|selumetinib

bevacizumab

KRAS exon 2 mutation|Colorectal Cancer|bevacizumab

panitumumab

KRAS exon 2 mutation|Colorectal Cancer|panitumumab

cetuximab

KRAS exon 2 mutation|Colorectal Cancer|cetuximab

erlotinib

KRAS exon 2 mutation|Non Small Cell Lung Cancer|erlotinib

KRAS exon 2 mutation|Pancreatic Cancer|erlotinib

gefitinib

KRAS exon 2 mutation|Non Small Cell Lung Cancer|gefitinib